

Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

SANOFI SYNTHELABO SA

Form S-8

July 22, 2003

As filed with the Securities and Exchange Commission on July 22, 2003

Registration No. 333-

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933

Sanofi-Synthelabo  
(Exact Name of Registrant as Specified in Its Charter)

France

133529324

(State or Other Jurisdiction of  
Incorporation or Organization)

(I.R.S. Employer Identification  
Number)

174 Avenue de France  
75013 Paris  
France

(Address of Registrant's Principal Executive Offices)

Stock Option Purchase Plan of Sanofi-Synthelabo  
(Full Title of the Plan)

John Spinnato  
Sanofi-Synthelabo Inc.  
90 Park Avenue  
New York, NY 10016  
212-551-4306

with a copy to:

Robert J. Raymond, Esq.  
Cleary, Gottlieb, Steen & Hamilton  
One Liberty Plaza  
New York, NY 10006

(Name, Address, and Telephone Number, Including Area Code, of Agent for Service)

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered (1)	Amount to be registered (2)	Proposed maximum offering price per share (3) (4)	Proposed maximum aggregat offering pr (3) (4)
---	--------------------------------	---	---

## Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

Ordinary shares, nominal value Euro 2 per share	191,300	\$48.47 (3)	\$ 9,272,3
Ordinary shares, nominal value Euro 2 per share	188,500	\$72.29 (3)	\$13,626,6
Ordinary shares, nominal value Euro 2 per share	217,100	\$78.38 (3)	\$17,016,2
Ordinary shares, nominal value Euro 2 per share	500,000	\$58.39 (4)	\$29,195,0
TOTAL	1,096,900		

(1) American Depositary Receipts (each an "ADR") evidencing American Depositary Shares (each an "ADS") issuable upon deposit of the ordinary shares registered hereby are registered pursuant to a separate Registration Statement on Form F-6 (Reg. No. 333-91658). Each ADS equals one-half of one Share.

(2) Together with an indeterminate number of shares that may be necessary in connection with any adjustment to the number of shares reserved for issuance pursuant to the Stock Option Purchase Plan of Sanofi-Synthelabo (the "Plan") as the result of a stock split, stock dividend or similar event affecting the outstanding ordinary shares of Sanofi-Synthelabo (the "Registrant" or the "Corporation").

(3) Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act of 1933, as amended (the "Securities Act"), with respect to ordinary shares of the Corporation (the "Shares") issuable pursuant to stock options previously granted to U.S. employees in calendar years between 1999 and 2002 pursuant to the Plan, based on the price at which such options may be exercised in Euros and converted into U.S. dollars based on the New York foreign exchange mid-range rate of Euro 1 = \$1.1207 as quoted at 4 p.m. Eastern time on July 17, 2003 by Reuters and other sources and as published in the Wall Street Journal on July 18, 2003 (the "Conversion Rate").

(4) Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, with respect to Shares issuable pursuant to stock options not yet granted under the Plan and based on the average of the high and low reported prices of the Shares on July 18, 2003, as converted into U.S. dollars based on the Conversion Rate. The average of the high and low reported price for one Share was Euro 52.10 on July 18, 2003.

### Part II

#### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

##### Item 3. Incorporation of Documents by Reference.

The following documents, which previously have been filed by the Corporation with the Securities and Exchange Commission (the "Commission"), are incorporated herein by reference and made a part hereof:

- (a) The Corporation's Annual Report on Form 20-F (Registration No.

## Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

001-31368) (the "Form 20-F Annual Report"), filed pursuant to the Securities Act of 1933, as amended (the "Securities Act"), with the Commission on June 23, 2003;

(b) The description of the ADSs contained under the heading "Description of Securities other than Equity Securities" and the description of the Shares under the headings "Additional Information - Share Capital" and "Additional Information - Memorandum and Articles of Association" in the Corporation's Form 20-F Annual Report; and

(c) All other reports filed by the Corporation pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") since December 31, 2002.

All reports and other documents filed by the Corporation pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment hereto, which indicates that all securities offered hereunder have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

For purposes of this Registration Statement, any document or any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded to the extent that a subsequently filed document or a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such document or such statement in such document. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4 Description of Securities.

Not applicable.

Item 5 Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

The Corporation maintains insurance under which its directors and officers are insured, within the limits and subject to the limitations of the policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been such directors or officers.

Item 7. Exemption From Registration Claimed.

Not applicable.

Item 8. Exhibits.

The following exhibits are filed with or incorporated by reference into this Registration Statement (numbering corresponds to Exhibit Table in Item 601 of Regulation S-K):

- 4.1 By-laws of Sanofi-Synthelabo (English translation) (filed as Exhibit 1.1 to the Form 20-F Annual Report and incorporated herein by reference)

## Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

- 4.2 Form of Deposit Agreement, by and among Sanofi-Synthelabo, The Bank of New York, as Depositary, and owners and beneficial owners of American Depositary Receipts (filed as Exhibit 2.1 to the Company's Registration Statement on Form 20-F (Reg. No. 001-31368), filed pursuant to the Securities Act on June 25, 2002 and incorporated herein by reference)
- 4.3 Resolution Number 29 of the General Meeting of the Shareholders of Sanofi-Synthelabo held on May 18, 1999 (English translation)
- 4.4 Form of Annual Rules of the Stock Option Purchase Plan of Sanofi-Synthelabo
- 23.1 Consent of Ernst & Young Audit, Independent Accountants with respect to Sanofi-Synthelabo financial statements
- 23.2 Consent of Pricewaterhousecoopers Audit, Independent Accountants with respect to Sanofi-Synthelabo financial statements
- 24.1 Powers of Attorney (included on signature page)

### Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of the prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the

## Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of the employee benefit plans' annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

### SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf, thereunto duly authorized, in the city of Paris, France on this \_\_\_\_ day of \_\_\_\_\_, 2003.

SANOFI-SYNTHELABO

By: \_\_\_\_\_

Name: Jean-Francois Dehecq

Title: Chairman and Chief Executive Officer

### POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Spinnato as his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead in any and all such capacities this Registration Statement and any and all amendments thereto (including post-effective amendments) and any documents in connection therewith, and to file the same with the Commission, said attorney-in-fact to have full power and authority to do and perform, in the name and on behalf of each such officer and

## Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

director of the Corporation who shall have executed such a power of attorney, every act whatsoever which such attorney-in-fact may deem necessary or desirable to be done in connection therewith as fully and to all intents and purposes as such officer or director of the Corporation might or could do in person.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the \_\_\_\_ day of \_\_\_\_\_, 2003.

Signature	Title
/s/ Jean-Francois Dehecq ----- Jean-Francois Dehecq	Chairman and Chief Executive Officer
/s/ Rene Barbier de la Serre ----- Rene Barbier de la Serre	Director
/s/ Robert Castaigne ----- Robert Castaigne	Director
/s/ Pierre Castres Saint Martin ----- Pierre Castres Saint Martin	Director
/s/ Thierry Desmarest ----- Thierry Desmarest	Director
/s/ Lord Douro ----- Lord Douro	Director
----- Pierre-Gilles de Gennes	Director
----- Herve Guerin	Director
/s/ Jean-Paul Leon ----- Elf Aquitaine, represented by Jean-Paul Leon	Director
/s/ Lindsay Owen Jones ----- Lindsay Owen Jones	Director
/s/ Gerard Van Kemmel ----- Gerard Van Kemmel	Director
/s/ Bruno Weymuller ----- Bruno Weymuller	Director
/s/ Michel Somnolet -----	Director

## Edgar Filing: SANOFI SYNTHELABO SA - Form S-8

L'Oreal, represented by  
Michel Somnolet

/s/ Marie-Helene Laimay ----- Marie-Helene Laimay	Senior Vice President, Chief Financial Officer
/s/ Jean-Luc Renard ----- Jean-Luc Renard	Vice President, Corporate Accounting and Tax
/s/ John Spinnato ----- John Spinnato	Authorized U.S. Representative and General Counsel of Sanofi-Synthelabo Inc.

### EXHIBIT INDEX

Exhibit Number	Description	Method of Filing
4.1	By-laws of Sanofi-Synthelabo (English translation)	Filed as Exhibit to the Corporation's Form 20-F Annual Report and incorporated here by reference
4.2	Form of Deposit Agreement, by and among Sanofi-Synthelabo, The Bank of New York, as Depositary, and owners and beneficial owners of American Depositary Receipts	Filed as Exhibit to the Company's Registration Statement on Form 20-F (Reg. No. 001-31368), filed pursuant to the Securities Act on June 25, 2002 and incorporated here by reference
4.3	Resolution Number 29 of the General Meeting of the Shareholders of Sanofi-Synthelabo held on May 18, 1999 (English translation)	Filed herewith
4.4	Form of Annual Rules of the Stock Option Purchase Plan of Sanofi-Synthelabo	Filed herewith
23.1	Consent of Ernst & Young Audit, Independent Accountants with respect to Sanofi-Synthelabo financial statements	Filed herewith
23.2	Consent of Pricewaterhousecoopers Audit, Independent Accountants with respect to Sanofi-Synthelabo financial statements	Filed herewith
24.1	Powers of Attorney (included on signature page)	Filed herewith